Despite COVID-19 epidemic, the chronic disease treatment market continued to grow. The market for antibiotics and expectorants declined significantly due to the decrease in cold patients due to strengthening hygiene management.

According to UBIST, a drug research institute on the 19th, the prescription amount of statin drugs used to treat dyslipidemia last year was ₩1 trillion, an increase of 3.4% from the previous year. The prescription amount in 2019 was ₩976.5 billion won, an increase of 2.9% from the previous year, but the growth rate was higher last year.

Statin sales increase every year. In 2017 and 2018, prescriptions increased 4.1% and 6.1% respectively from the previous